secwatch.observer — SEC 8-K summary
======================================

Issuer:     DELCATH SYSTEMS, INC. (DCTH)
CIK:        0000872912
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001628280-23-038607
Event type: earnings
Sentiment:  positive
Materiality: 1.00
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Delcath reports Q3 results; FDA approved HEPZATO KIT, launch planned Jan 2024
-----------------------------------------------------------------------------

- FDA approved HEPZATO KIT for metastatic uveal melanoma with hepatic metastases; commercial launch planned for January 2024.
- Raised ~$35M from Tranche A warrant exercise; up to $25M more upon achieving $10M quarterly revenue.
- Q3 revenue $0.4M vs $0.9M YoY; R&D $4.7M, SG&A $6.2M.
- Retrospective study showed median overall survival 516 days for PHP vs 301 days for SIRT in metastatic uveal melanoma.
- CHOPIN trial enrolled 55 of 76 patients; interim futility analysis recommended continuing; full enrollment expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872912/000162828023038607/0001628280-23-038607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872912/000162828023038607/dcth-20231113.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer